Pharmaceutical Trademark Registration in Pakistan: DRAP & IPO Requirements
A pharmaceutical brand name in Pakistan needs two separate approvals — DRAP registration of the drug product itself, and IPO-Pakistan trademark registration of the name — and getting one does not automatically secure the other, or protect against a confusingly similar name being approved for a different drug.
Pharmaceutical companies sometimes assume that once the Drug Regulatory Authority of Pakistan (DRAP) approves a brand name for a drug product, the name is protected. It isn't — DRAP approval and trademark registration are two different processes run by two different authorities, and neither automatically secures the other.
Two separate processes, not one
DRAP's role, under the Drug Act 1976, is to review and register the drug product itself — approving the brand name as part of that process to reduce the risk of prescribing or dispensing confusion between products. Trademark registration with the Intellectual Property Organization of Pakistan is a separate legal process that establishes ownership rights in the name itself, independent of whether or which drug product it's attached to. A company that only completes DRAP registration has a regulatory approval, not an enforceable trademark right against a competitor using a similar name on a different product category.
The confusingly-similar-name problem
Despite DRAP's own review process, cases of identical or closely similar brand names being registered for different therapeutic products do occur in Pakistan — a real risk that is as much a patient-safety issue (medication errors from name confusion) as a commercial one. Firms handling pharmaceutical trademark disputes in Pakistan regularly see infringement matters arising from exactly this kind of naming overlap, which is part of why the trademark filing needs to happen independently of, not instead of, the DRAP process.
Why filing with IPO early protects more than the product name
A trademark application filed with IPO-Pakistan before or alongside the DRAP submission gives a documented priority date and a route to actually enforce against a later, confusingly similar name — something DRAP approval alone does not provide. It also covers the mark across the trademark classes relevant to pharmaceuticals and related goods, which matters if the company later extends the brand to related product lines DRAP's drug-specific approval wouldn't cover.
What to do if a similar name appears
Where a confusingly similar brand name has already been approved by DRAP for a different product, the trademark route — opposition if the conflicting mark hasn't yet registered, or infringement action if it has — generally offers a more direct remedy than raising the naming conflict with DRAP alone, since DRAP's remit is drug safety and registration, not adjudicating trademark rights between two brand owners.
This article is general information about Pakistani law and procedure, not legal advice for any specific matter. If this touches on something you're currently facing, get in touch and we'll advise on your facts directly.